Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26503989 | 0.80 | HTR2A (0.36) | OPRL1NISCH | |
| SCHEMBL30054577 | 0.76 | EPAS1 (0.36) | — | |
| SCHEMBL28387436 | 0.76 | OPRL1 (0.32) | OPRL1 | |
| SCHEMBL30686720 | 0.70 | EPAS1 (0.37) | — | |
| SCHEMBL24387388 | 0.70 | EPAS1 (0.37) | — | |
| SCHEMBL23846917 | 0.69 | — | — | |
| SCHEMBL16359911 | 0.69 | F12 (0.40) | — | |
| SCHEMBL17513185 | 0.66 | MEN1 (0.41) | — | |
| SCHEMBL10840512 | 0.66 | HTR2C (0.45) | — | |
| SCHEMBL20804675 | 0.66 | MAP3K14 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210317079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021188769-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | OPRL1 3838/4885NISCH 2491/4885 |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | OPRL1 3838/4885NISCH 2491/4885 |
| US-20210317079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | OPRL1 3838/4885NISCH 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.